LISATA THERAPEUTICS, INC.

LSTA

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 18, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Auto-CD34+ cells	Phase 3	Chronic Myocardial Ischemia	-
therapeutic autologous dendritic cells	Phase 2	Melanoma (Skin)	-
CLBS16	Phase 2	Coronary Microvascular Dysfunction	-
NBS10	Phase 2	ST Segment Elevation Myocardial Infarction	-
CLBS14 (low-dose)	Phase 2	Myocardial Ischemia	-
CLBS03 Low Dose	Phase 2	Diabetes Mellitus	-
CLBS12	Phase 2	Critical Limb Ischemia	-
certepetide	Phase 2	Cholangiocarcinoma	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Apr 18, 2026certepetide

Primary completion for certepetide trial (NCT05712356) in Cholangiocarcinoma

Regulatory Approvals

LSTA News